Enovis (ENOV) Stock Price, News & Analysis

Company Overview

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone. Enovis also provides orthobiologic solutions and surgical accessories via EBI, as well as custom and off-the-shelf orthotic braces and supports through its SmartStep and LITOS product lines.

Enovis serves surgeons, hospitals and rehabilitation specialists across North America, Europe and select Asia-Pacific regions, leveraging an integrated commercial network of direct sales teams and distribution partners. The company invests in clinical research and training programs to support product adoption, surgical education and patient outcomes.

Headquartered in Pittsburgh, Pennsylvania, Enovis is led by an executive team with extensive experience in medical device innovation and global market development. The company remains committed to expanding its portfolio through targeted acquisitions and continued R&D aimed at improving functional recovery and quality of life for patients worldwide.

Key Stats

• Today's Range: $30.00 to $30.49
• 50-Day Range: $25.77 to $33.30
• 52-Week Range: $25.47 to $49.83
• Volume: 133,413 shs
• Average Volume: 1.13 million shs
• Market Capitalization: $1.72 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.00
• Consensus Rating: Moderate Buy

Enovis Stock Analysis - MarketRank™

Enovis scored higher than 73% of companies evaluated by MarketBeat, and ranked 278th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Enovis has a consensus price target of $51.00, representing about 69.1% upside from its current price of $30.16.

Amount of Analyst Coverage

Enovis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 14.34%

Earnings Growth

Earnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enovis is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enovis is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enovis has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.39% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Enovis has recently increased by 0.43%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enovis does not currently pay a dividend.

Dividend Growth

Enovis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.39% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Enovis has recently increased by 0.43%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.98

News Sentiment

Enovis has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Enovis this week, compared to 6 articles on an average week.

Search Interest

Only 6 people have searched for ENOV on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Enovis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $374,760.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.70% of the stock of Enovis is held by insiders.

Percentage Held by Institutions

98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENOV Stock Analysis - Frequently Asked Questions

How have ENOV shares performed this year?

Enovis' stock was trading at $43.88 on January 1st, 2025. Since then, ENOV stock has decreased by 31.3% and is now trading at $30.1550.

How were Enovis' earnings last quarter?

Enovis Corporation (NYSE:ENOV) released its quarterly earnings results on Monday, January, 8th. The company reported $0.59 earnings per share for the quarter. The business had revenue of $383.81 million for the quarter. Enovis had a positive trailing twelve-month return on equity of 6.78% and a negative net margin of 37.80%.

Who are Enovis' major shareholders?

Top institutional investors of Enovis include Assenagon Asset Management S.A. (0.23%), Central Valley Advisors LLC (0.11%), Wedge Capital Management L L P NC (0.09%) and Dynamic Advisor Solutions LLC (0.05%). Insiders that own company stock include Matthew L Trerotola, Phillip Benjamin (Ben) Berry, Daniel A Pryor, Brady Shirley, Christopher M Hix, Bradley J Tandy, A Clayton Perfall, Patricia A Lang, Rajiv Vinnakota and John Kleckner.
View institutional ownership trends.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enovis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 1/08/2024
• Today: 10/13/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ENOV
• CIK: 1420800
• Web: www.enovis.com
• Phone: 302-252-9160
• Fax: 301-323-9001
• Employees: 7,367
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Enovis: $51.00
• High Price Target: $58.00
• Low Price Target: $41.00
• Potential Upside/Downside: +71.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 10.64
• P/E Growth: N/A
• Net Income: -$825.49 million
• Net Margins: -37.80%
• Pretax Margin: -36.51%
• Return on Equity: 6.78%
• Return on Assets: 3.73%

Debt

• Debt-to-Equity Ratio: 0.53
• Current Ratio: 2.25
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $2.11 billion
• Price / Sales: 0.81
• Cash Flow: $19.28 per share
• Price / Cash Flow: 1.54
• Book Value: $45.10 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 57,160,000
• Free Float: 55,617,000
• Market Cap: $1.70 billion
• Optionable: Optionable
• Beta: 1.69